Search results
Psoriasis study shows high level of arthritis symptoms in patients
Medical Xpress· 6 days agoThe study led by researchers at the Universities of Oxford, University College Dublin and supported...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 1 day agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Why Is My Skin So Itchy?
Verywell Health via Yahoo News· 6 days agoPruritus, or itchy skin, is a characteristic feature of many skin diseases and an unusual sign of some systemic diseases. It can be painful or...
Capsaicin: The kick from your chilli can have side effects
BBC News· 12 hours agoCan it really be a danger to health? The cause of these concerns is capsaicin, the active component...
Why Diabetes, High Blood Pressure and More Conditions Can Make Heatwaves Dangerous
CNET· 2 days agoA heat wave has stifled parts of the US this week, with people across the Midwest and Northeast...
Polycystic Ovarian Syndrome: New Science Offers Old Remedy
Medscape· 7 days agoAn ancient Chinese remedy for malaria could offer new hope to the 10% of reproductive-age women...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 5 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 6 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 5 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 4 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...